A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms PATHWAY
  • Sponsors MedImmune
  • Most Recent Events

    • 13 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2017 This trial was completed in Bulgaria (end date: 2017-03-01), according to European Clinical Trials Database.
    • 19 Mar 2017 This trial has been completed in Lithuania (end date: 1 Mar 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top